Immunovant, Inc. (IMVT) stock analysis

In our weekly check, Immunovant, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10.

About Immunovant, Inc.

Immunovant, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IMVT.

What our checks show for IMVT

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-05

Similar companies

TXG · ORKA · KOD · TWST · ARWR · AXSM

Questions

What grade does Immunovant, Inc. (IMVT) have?

In our weekly check, Immunovant, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of IMVT stock?

This week's biggest flags for Immunovant, Inc.: Margins falling, Weak EPS forecast, Weak EPS growth. In total 12 of 21 checks show a warning or a red flag.

What does Immunovant, Inc. do?

Immunovant, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IMVT.

When does Immunovant, Inc. report earnings next?

The next earnings report is expected on 2027-02-05. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis